On Monday, Jan. 7, Michael Lavery at Piper Sandler initiated coverage of the beverage giant, with an overweight rating and a ...

Transocean (NYSE:RIG – Free Report) had its target price cut by TD Cowen from $6.50 to $5.50 in a research note issued to ...

TD Cowen analyst Andrew Kligerman upgraded Arthur J. Gallagher (AJG) to Buy from Hold with a price target of $377, up from $295, following the ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today. The company’s shares opened ...

Fintel reports that on January 8, 2025, TD Cowen downgraded their outlook for J. M. Smucker (NYSE:SJM) from Buy to Hold.

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Hold to ...

Investment analysts at TD Cowen began coverage on shares of CG Oncology (NASDAQ:CGON – Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The ...

The cost of prescription drugs is set to climb in 2025 and beyond, according to TD Cowen’s 30th Annual Drug Pricing survey.

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

“Two-thousand-twenty-four was a tough year for staples stocks, and 2025 is shaping up to be even tougher,” says TD Cowen ...

Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, discusses some of the key findings of a new TD Cowen report on the big investment themes of 2025, including shifting ...